MannKind (MNKD) Revenue & Revenue Breakdown
MannKind Revenue Highlights
Latest Revenue (Y)
$285.50M
Latest Revenue (Q)
$78.35M
Main Segment (Y)
Royalty
MannKind Revenue by Period
MannKind Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $285.50M | 43.50% |
| 2023-12-31 | $198.96M | 99.42% |
| 2022-12-31 | $99.77M | 32.25% |
| 2021-12-31 | $75.44M | 15.81% |
| 2020-12-31 | $65.14M | 3.34% |
| 2019-12-31 | $63.04M | 126.28% |
| 2018-12-31 | $27.86M | 137.20% |
| 2017-12-31 | $11.74M | -93.28% |
| 2016-12-31 | $174.76M | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2013-12-31 | - | -100.00% |
| 2012-12-31 | $35.00K | -30.00% |
| 2011-12-31 | $50.00K | -46.24% |
| 2010-12-31 | $93.00K | 100.00% |
| 2009-12-31 | - | -100.00% |
| 2008-12-31 | $20.00K | 100.00% |
| 2007-12-31 | $10.00K | -90.00% |
| 2006-12-31 | $100.00K | 100.00% |
| 2005-12-31 | - | 100.00% |
| 2004-12-31 | - | 100.00% |
| 2003-12-31 | - | 100.00% |
| 2002-12-31 | - | -100.00% |
| 2001-12-31 | $326.00K | 111.69% |
| 2000-12-31 | $154.00K | - |
MannKind generated $285.50M in revenue during NA 2024, up 43.50% compared to the previous quarter, and up 452.91% compared to the same period a year ago.
MannKind Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-03-31 | $78.35M | 2.06% |
| 2024-12-31 | $76.78M | 9.56% |
| 2024-09-30 | $70.08M | -3.19% |
| 2024-06-30 | $72.39M | 9.24% |
| 2024-03-31 | $66.26M | 13.32% |
| 2023-12-31 | $58.47M | 14.09% |
| 2023-09-30 | $51.25M | 5.43% |
| 2023-06-30 | $48.61M | 19.65% |
| 2023-03-31 | $40.63M | 12.67% |
| 2022-12-31 | $36.06M | 9.85% |
| 2022-09-30 | $32.83M | 73.73% |
| 2022-06-30 | $18.89M | 57.56% |
| 2022-03-31 | $11.99M | -4.18% |
| 2021-12-31 | $12.52M | -43.65% |
| 2021-09-30 | $22.21M | -4.59% |
| 2021-06-30 | $23.28M | 33.52% |
| 2021-03-31 | $17.44M | -5.46% |
| 2020-12-31 | $18.44M | 20.13% |
| 2020-09-30 | $15.35M | 1.57% |
| 2020-06-30 | $15.11M | -6.90% |
| 2020-03-31 | $16.23M | 1.51% |
| 2019-12-31 | $15.99M | 9.58% |
| 2019-09-30 | $14.60M | -2.71% |
| 2019-06-30 | $15.00M | -14.02% |
| 2019-03-31 | $17.45M | 8.83% |
| 2018-12-31 | $16.03M | 258.74% |
| 2018-09-30 | $4.47M | 14.80% |
| 2018-06-30 | $3.89M | 12.35% |
| 2018-03-31 | $3.46M | -23.51% |
| 2017-12-31 | $4.53M | 121.73% |
| 2017-09-30 | $2.04M | -5.55% |
| 2017-06-30 | $2.16M | -28.12% |
| 2017-03-31 | $3.01M | -75.74% |
| 2016-12-31 | $12.40M | -92.36% |
| 2016-09-30 | $162.35M | 100.00% |
| 2016-06-30 | - | 100.00% |
| 2016-03-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2015-09-30 | - | 100.00% |
| 2015-06-30 | - | 100.00% |
| 2015-03-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2014-09-30 | - | 100.00% |
| 2014-06-30 | - | 100.00% |
| 2014-03-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2013-09-30 | - | 100.00% |
| 2013-06-30 | - | 100.00% |
| 2013-03-31 | - | 100.00% |
| 2012-12-31 | - | -100.00% |
| 2012-09-30 | $35.00K | 100.00% |
| 2012-06-30 | - | 100.00% |
| 2012-03-31 | - | 100.00% |
| 2011-12-31 | - | 100.00% |
| 2011-09-30 | - | 100.00% |
| 2011-06-30 | - | -100.00% |
| 2011-03-31 | $50.00K | 100.00% |
| 2010-12-31 | - | 100.00% |
| 2010-09-30 | - | -100.00% |
| 2010-06-30 | $93.00K | 100.00% |
| 2010-03-31 | - | 100.00% |
| 2009-12-31 | - | 100.00% |
| 2009-09-30 | - | 100.00% |
| 2009-06-30 | - | 100.00% |
| 2009-03-31 | - | 100.00% |
| 2008-12-31 | - | 100.00% |
| 2008-09-30 | - | 100.00% |
| 2008-06-30 | - | -100.00% |
| 2008-03-31 | $20.00K | 100.00% |
| 2007-12-31 | - | - |
MannKind generated $78.35M in revenue during Q1 2025, up 2.06% compared to the previous quarter, and up 134.00% compared to the same period a year ago.
MannKind Revenue Breakdown
MannKind Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|---|
| License and Service | $100.84M | $41.91M | - | - | - |
| Royalty | $102.33M | $15.60M | - | - | - |
| Product | $82.33M | $56.25M | $39.17M | $32.32M | - |
| Product Sales | - | - | $81.07M | - | - |
| Service | - | - | $3.10M | - | - |
| License And Service | - | - | - | $22.02M | $9.56M |
Latest
MannKind's latest annual revenue breakdown by segment (product or service), as of Dec 24: Royalty (35.84%), License and Service (35.32%), and Product (28.84%).
Quarterly Revenue by Product
| Product/Service | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Service | $621.00K | $513.00K | $430.00K | $1.17M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Product Revenue | $44.68M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Royalty | $31.23M | $30.00M | $75.25M | $27.08M | $9.07M | $6.22M | $304.00K | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Product | - | $18.97M | $62.60M | $19.73M | $17.44M | $16.26M | $12.72M | $9.83M | $11.34M | $9.75M | $10.06M | $7.28M | - | - | - | - | - | - | - | - |
| License And Service | - | $29.38M | $23.27M | $14.78M | $10.68M | $8.71M | $7.14M | $6.08M | $5.51M | $3.29M | $2.63M | $1.58M | $1.98M | - | - | - | - | - | - | - |
| License and Service | - | - | - | - | - | $22.64M | $10.26M | $9.01M | - | - | - | - | - | - | - | - | - | - | - | - |
| Product Sales | - | - | - | - | - | - | - | - | - | $26.47M | $26.18M | $17.42M | - | - | - | - | - | - | - | - |
Latest
MannKind's latest quarterly revenue breakdown by segment (product or service), as of Jun 25: Product Revenue (58.38%), Royalty (40.81%), and Service (0.81%).
MannKind Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| HRMY | Harmony Biosciences | $714.73M | $200.49M |
| NVAX | Novavax | $682.16M | $239.24M |
| IMCR | Immunocore | $310.20M | $97.96M |
| MNKD | MannKind | $285.50M | $78.35M |
| RCUS | Arcus Biosciences | $258.00M | $28.00M |
| AUPH | Aurinia Pharmaceuticals | $235.13M | $70.01M |
| ABCL | AbCellera Biologics | $28.83M | $4.24M |
| JANX | Janux Therapeutics | $10.59M | - |
| PHVS | Pharvaris | - | - |
| VRDN | Viridian Therapeutics | - | - |
| EWTX | Edgewise Therapeutics | - | - |